# Phase I Trial of GR1803 Injection in Patients With RRMM

> **NCT07102706** · PHASE1,PHASE2 · COMPLETED · sponsor: **Genrix (Shanghai) Biopharmaceutical Co., Ltd.** · enrollment: 76 (actual)

## Conditions studied

- Multiple Myeloma (MM)

## Interventions

- **DRUG:** GR1803 injection

## Key facts

- **NCT ID:** NCT07102706
- **Lead sponsor:** Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-27
- **Primary completion:** 2025-05-20
- **Final completion:** 2025-05-20
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2025-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07102706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07102706, "Phase I Trial of GR1803 Injection in Patients With RRMM". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07102706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*